Markets:

Overview

News

Currencies

International

Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

4.675 +0.195 (+4.35%)

Streaming Delayed Price Updated: 2:21 PM EDT, Apr 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arbutus Biopharma Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Mid-Day Market Update: Build-A-Bear Jumps After Q3 Results; BeyondSpring Shares Slide ↗

December 01, 2021

Midway through trading Wednesday, the Dow traded up 1.06% to 34,847.76 while the NASDAQ climbed 1.17% to 15,719.00. The S&P also rose, gaining 1.48% to 4,634.64. The U.S. has...

Via Benzinga

Topics Stocks

50 Stocks Moving In Wednesday's Mid-Day Session ↗

December 01, 2021

Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) climbed 91.7% to $6.14 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down Moderna's...

Via Benzinga

Topics Intellectual Property

Understanding Arbutus Biopharma's Unusual Options Activity ↗

August 11, 2021

Arbutus Biopharma (NASDAQ:ABUS) shares experienced unusua...

Via Benzinga

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗

August 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

Why Arbutus Biopharma Is Rocketing Higher Today ↗

December 01, 2021

A recent court of appeals decision is bad news for Moderna and great news for Arbutus Biopharma.

Via The Motley Fool

Topics Intellectual Property

Why Moderna Shares Are Sliding Today ↗

December 01, 2021

Moderna Inc (NASDAQ: MRNA) is trading lower Wednesday after The Patent Trial and Appeals Board turned down the company's appeal to invalidate two of Arbutus Biopharma...

Via Benzinga

Topics Intellectual Property

Arbutus Shares Are Soaring As Moderna Loses Appeal Of Board Ruling On COVID-19 Vaccine Delivery Technology Patent ↗

December 01, 2021

Shares of small-cap biotech Arbutus Biopharma Corporation (NASDAQ: ABUS) are advancing strongly on above-average volume on Wednesday. What Happened: The Patent Trial and Appeals...

Via Benzinga

Topics Intellectual Property

Mid-Morning Market Update: Markets Open Higher; G-III Apparel Earnings Beat Views ↗

December 01, 2021

Following the market opening Wednesday, the Dow traded up 0.99% to 34,824.47 while the NASDAQ climbed 1.40% to 15,755.57. The S&P also rose, gaining 1.39% to 4,630.57. The U.S...

Via Benzinga

Topics Earnings Stocks

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

November 08, 2021

Welcome back, trader! We're starting off the week strong with a dive into the biggest pre-market stock movers for Monday.

Via InvestorPlace

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

26 Stocks Moving in Monday's Pre-Market Session ↗

November 08, 2021

Gainers Autolus Therapeutics plc (NASDAQ: AUTL) rose 32.6% to $7.37 in pre-market trading. Syncona said Blackstone Life Science will invest $250 million in Autolus. Mainz Biomed...

Via Benzinga

Arbutus Biopharma (ABUS) Q3 2021 Earnings Call Transcript ↗

November 04, 2021

ABUS earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

21 Stocks Moving in Monday's Pre-Market Session ↗

October 18, 2021

Gainers Valneva SE (NASDAQ: VALN) rose 34.4% to $37.69 in pre-market trading after the company disclosed positive Phase 3 results for inactivated, adjuvanted COVID-19 vaccine...

Via Benzinga

41 Stocks Moving In Friday's Mid-Day Session ↗

September 10, 2021

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares climbed 64.4% to $14.29 after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in geographic...

Via Benzinga

60 Biggest Movers From Friday ↗

September 13, 2021

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in...

Via Benzinga

20 Stocks Moving in Friday's Pre-Market Session ↗

September 10, 2021

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) rose 29.6% to $11.26 in pre-market trading. Iveric Bio recently reported inducement grants under Nasdaq Listing Rule 5635(c)(4). T2...

Via Benzinga

48 Biggest Movers From Yesterday ↗

September 10, 2021

Gainers Rocket Lab USA, Inc. (NASDAQ: RKLB) jumped 37.3% to settle at $20.72. Rocket Lab reported 1H sales of $29.5 million and announced it has been awarded a contract to deploy...

Via Benzinga

46 Biggest Movers From Yesterday ↗

August 19, 2021

Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares climbed 189.5% to close at $9.90 on Wednesday after surging over 15% on Tuesday. SGOCO Group, Ltd. (NASDAQ: SGOC) surged 67...

Via Benzinga

66 Biggest Movers From Yesterday ↗

August 18, 2021

Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND...

Via Benzinga

Arbutus Biopharma (ABUS) Q2 2021 Earnings Call Transcript ↗

August 07, 2021

ABUS earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

28 Stocks Moving in Friday's Pre-Market Session ↗

August 06, 2021

Gainers Sphere 3D Corp. (NASDAQ: ANY) shares rose 35.4% to $4.66 in pre-market trading after the company reported an Agreement to acquire exclusive rights for assignment of...

Via Benzinga

26 Stocks Moving in Thursday's Pre-Market Session ↗

August 05, 2021

Gainers Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares rose 34% to $5.48 in pre-market trading after dropping around 15% on Wednesday. Ensysce Biosciences recently appointed...

Via Benzinga

The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend ↗

July 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6) Ambrx Biopharma Inc. (NYSE:...

Via Benzinga

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

Bullish Arbutus Biopharma Analyst Breaks Down Pipeline Opportunity ↗

July 06, 2021

The expected start of combination clinical trials has H.C. Wainwright bullish on shares of Arbutus Biopharma Corp. (NASDAQ:

Via Benzinga

Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B ↗

July 06, 2021

Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B...

Via Benzinga

The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout ↗

June 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,...

Via Benzinga

Arbutus Biopharma Stock Jumps On Encouraging Data From Hepatitis B Candidate ↗

June 28, 2021

Arbutus Biopharma Corporation (NASDAQ: ABUS) announced the presentation of five abstracts at the European Association for the Study of the Liver International Liver Congress...

Via Benzinga

24 Stocks Moving in Monday's Pre-Market Session ↗

June 28, 2021

Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim...

Via Benzinga

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗

June 20, 2021

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.

Via Talk Markets

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.